Ensysce Biosciences, Inc. (NASDAQ: ENSC), a clinical-stage pharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported cash and cash equivalents of $4.3 million as of December 31, 2025, an increase from $3.5 million in the previous year. Operating expenses for the fourth quarter were $4.7 million, with a net loss of $2.8 million compared to a net loss of $3.6 million for the same period in 2024. For the full year, the net loss was $10.2 million, up from $8.0 million in 2024. The company highlighted significant clinical advancements, including the initiation of a Phase 3 trial for its lead drug candidate, PF614, and constructive dialogue with the FDA regarding its manufacturing pathway. Ensysce also reported progress in its MPAR technology, which aims to provide overdose protection for opioid medications. The company is optimistic about its future prospects as it continues to strengthen its intellectual property portfolio and advance its clinical programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.